A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer · c-MET
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 150 (planned)
- Started
- Jan 20, 2025
- Main results expected
- Feb 2028
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Measured over: Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Measured over: Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Measured over: Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Measured over: Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Measured over: Up to Approximately 3 Years
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Measured over: Up to Approximately 3 Years
Objective Response (OR) by Blinded Independent Central Review (BICR)
Measured over: Up to Approximately 3 Years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06568939 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC